This Month
Sunscreen regulation faces overhaul after SPF failures
The Therapeutic Goods Administration is moving to restore public trust after an investigation found many products failed to meet their label claims.
People are dumping their top-tier health insurance
The exodus is expected to accelerate when average premiums increase by 4.4 per cent from April 1, the largest annual hike in almost a decade.
Citi hires Goldman Sachs healthcare banker as Katrina Efthim exits
Ben Bartholomaeus is jumping ship to head up Citi’s healthcare advisory for Australia and New Zealand.
NDIS providers increasing fees without improving service: analysis
The National Disability Insurance Scheme pricing model encourages providers to bump up their fees without increasing services, an analysis shows.
Olympian turned doctor takes the plunge in $1.4b ice bath market
Matt Guest has brought in former Australian cricket captain Tim Paine and is raising $2 million to make an easy-to-use backyard ice plunge a reality.
Healthscope’s La Spina ousted after bust-up with receivers
The former Qantas executive has been removed as CEO of the failed hospitals operator, despite insisting he remains in the role.
Poo patrol and sensory gardens: The NDIS can pay for that
Sex, drugs and alcohol are banned from the NDIS, but many other items including skiing, kayaking and surfing are still in a grey zone.
Regal-backed Immutep dives 90pc after it abandons cancer drug trial
More than $500 million was wiped from the company’s market capitalisation in a blow to major investors including the Phil King-run fund management giant.
Healthscope shrinks in size as Adelaide hospitals exit the group
Australia’s second-biggest private hospital group lost three Adelaide hospitals from its network, although it said this would not impact its not-for-profit plan.
CDC boss says data, public trust must improve to handle next pandemic
The boss of the new Australian Centre for Disease Control says mistakes are inevitable in pandemics, but COVID-19 was handled better here than in other countries.
Monash IVF settles lawsuit with families linked to embryo mix-ups
The fertility company had told investors insurance would cover settlements after a mix-up resulted in a patient giving birth to someone else’s baby.
The fatty liver epidemic: Why millions of Australians are at risk
It’s the most common ailment for this organ in the country, but treatment is limited to diet and exercise. Researchers are looking for a medical breakthrough.
Swiss giant Partners Group circles collapsed Priceline chain Infinity
Should Hartz progress with submitting a proposal for Infinity, it will lock horns with sector gorilla Chemist Warehouse and private equity firms like Sydney’s Genesis Capital.
BGH Capital woos co-investors for $2.4b pharmaceutical bet
The moves comes after BGH quietly announced the acquisition of Aspen Pharmacare’s Asia Pacific business in the final days of 2025.
February
‘More regulation to pull a beer’: NDIS providers under fire
The sheer volume of unregistered NDIS providers who do not have to comply to specific standards has raised further integrity and sustainability concerns.
Weight-loss drugs drive double-digit Chemist Warehouse sales
The popularity of the medication is boosting sales in hair and beauty products at the pharmacies giant, and a new oral version will drive demand even higher.
Ramsay earnings rise points to hospital giant’s turnaround
Investors in the country’s largest private health group were buoyed by the result, which they said showed chief executive Natalie Davis’ strategy was working.
Why a $10b autism bill is forcing a rethink of the NDIS
The number of older children and adults being diagnosed with it under the National Disability Insurance Scheme is surging, costing taxpayers far more each year.
Blackbird reveals the eye-popping returns from its big Eucalyptus bet
The Australian telehealth unicorn announced its $1.6 billion sale to New York-listed Hims & Hers last year, minting a string of immediate millionaires.
Sonic Healthcare lists $500m Brisbane laboratory for sale
The ASX-listed healthcare provider is offering a sale and leaseback deal at a time when the medical real estate sector is expected to double in value by 2028.
